Raynaud's phenomenon is present almost uniformly in MCTD. Patients who present with Raynaud's phenomenon and a high anti-U1-RNP antibody titer should be watched closely for features of MCTD. In particular, nailfold capillary findings are helpful to distinguish these patients from those who have primary Raynaud's phenomenon. Cardiopulmonary complications, including pulmonary hypertension, are a risk among patients who present with Raynaud's phenomenon and anti-U1-RNP antibodies. Although Raynaud's phenomenon tends to be less severe in patients who have MCTD compared with those who have scleroderma, its pathogenesis seems to be similar. Specific recommendations for therapy for Raynaud's phenomenon in MCTD are not yet established, but it makes sense to follow the management that is used in patients who have scleroderma.
ASJC Scopus subject areas